Arch Therapeutics, Inc.
Arch Therapeutics, Inc. (ARTH) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · ARTH · as of Jun 9, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
0
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Arch Therapeutics, Inc. insiders have shown mixed buying and selling activity over the past 12 Months.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
ARTH insider buying and selling by quarter
ARTH insider selling · ARTH insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Recent insider transactions
ARTH executive sell shares · ARTH board member insider trading · ARTH insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Aug 31, 2023 | ABRAMS MICHAEL S CHIEF FINANCIAL OFFICER | Purchase | 10,292 | $3K | Form 4 |
| Aug 31, 2023 | Norchi Terrence W PRESIDENT AND CHIEF EXECUTIVE · Director | Purchase | 6,862 | $2K | Form 4 |
| Aug 31, 2023 | Hicks Laurence Director | Purchase | 10,292 | $3K | Form 4 |
| Jul 6, 2022 | ABRAMS MICHAEL S CHIEF FINANCIAL OFFICER | Award | 108,652 | — | Form 4 |
| Jul 6, 2022 | Norchi Terrence W Director | Award | 72,435 | — | Form 4 |
| Jul 30, 2021 | Yrigoyen Dan Vice President, Sales | Award | 150,000 | — | Form 4 |
| Jun 22, 2020 | SULAT JAMES R Director | Other | 454,546 | $37.19B⚡ | Form 4 |
| Jul 19, 2018 | SULAT JAMES R Director | Award | 110,000 | — | Form 4 |
| Jul 19, 2018 | Norchi Terrence W President & CEO · Director | Award | 360,000 | — | Form 4 |
| Jul 19, 2018 | DAVIS RICHARD E CFO & Treasurer | Award | 275,000 | — | Form 4 |
| Jul 19, 2018 | DHILLON AVTAR S Director | Award | 220,000 | — | Form 4 |
| Jul 16, 2018 | SULAT JAMES R Director | Option | 30,000 | $11K | Form 4 |
| Feb 3, 2017 | SULAT JAMES R Director | Award | 200,000 | — | Form 4 |
| Feb 3, 2017 | Norchi Terrence W President & CEO · Director | Award | 650,000 | — | Form 4 |
| Feb 3, 2017 | DHILLON AVTAR S Director | Award | 400,000 | — | Form 4 |
| Feb 3, 2017 | DAVIS RICHARD E CFO & Treasurer | Award | 500,000 | — | Form 4 |
| May 26, 2016 | SULAT JAMES R Director | Purchase | 111,111 | $40K | Form 4 |
| May 3, 2016 | Norchi Terrence W President & CEO · Director | Award | 1,130,000 | — | Form 4 |
| May 3, 2016 | DAVIS RICHARD E CFO & Treasurer | Award | 103,000 | — | Form 4 |
| May 3, 2016 | SULAT JAMES R Director | Award | 30,000 | — | Form 4 |
| May 3, 2016 | DHILLON AVTAR S Director | Award | 737,000 | — | Form 4 |
| Jun 26, 2013 | Norchi Terrence W Pres, CEO, Sec, and Treas · Director | Other | 1,419,076 | — | Form 4 |
| Jun 25, 2013 | DHILLON AVTAR S Director | Other | 160,373 | — | Form 4 |
ABRAMS MICHAEL S
CHIEF FINANCIAL OFFICER
Date
Aug 31
Shares
10,292
Price
$0.28
Value
$3K
Norchi Terrence W
PRESIDENT AND CHIEF EXECUTIVE · Director
Date
Aug 31
Shares
6,862
Price
$0.28
Value
$2K
ABRAMS MICHAEL S
CHIEF FINANCIAL OFFICER
Date
Jul 6
Shares
108,652
Price
—
Value
—
Norchi Terrence W
President & CEO · Director
Date
Jul 19
Shares
360,000
Price
—
Value
—
Norchi Terrence W
President & CEO · Director
Date
Feb 3
Shares
650,000
Price
—
Value
—
Norchi Terrence W
President & CEO · Director
Date
May 3
Shares
1,130,000
Price
—
Value
—
Norchi Terrence W
Pres, CEO, Sec, and Treas · Director
Date
Jun 26
Shares
1,419,076
Price
—
Value
—
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About ARTH insider trading
ARTH insider trades
Arch Therapeutics, Inc. (ARTH) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including ARTH. Over the past 12 months, 0 insiders have filed transactions with the SEC. ARTH insiders have been mixed buying and selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Arch Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
ARTH insider trading · 5 questionsThe insiders of Arch Therapeutics, Inc. (ARTH) include executives and directors such as ARTH, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026